| Title: | Genome-wide associations with metabolic syndrome among UK Biobank participants reporting use of second-generation antipsychotics |
| Journal: | Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy |
| Published: | 5 Aug 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40762455/ |
| DOI: | https://doi.org/10.1002/phar.70041 |
| URL: | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/phar.70041 |
Publication 16030
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
OBJECTIVES: Second-generation antipsychotic (SGA) medications are frequently prescribed for mental health conditions; however, they are associated with an increased risk of metabolic syndrome (MetS). We aimed to identify genetic associations of SGA-associated MetS (SGA-MetS) using genome-wide approaches within the UK Biobank. We also set out to evaluate if genetically predicted obesity is associated with an increased risk of SGA-MetS.</p>
METHODS: We defined SGA-MetS based on the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria using cross-sectional data from 1318 UK Biobank participants who reported being on an SGA medication. An SGA-MetS case was defined as meeting three or more of the five NCEP-ATP III criteria. We performed a genome-wide association study (GWAS) and gene-based analysis to identify significant variants and gene associations. We computed the polygenic risk score (PGS) for body mass index (BMI) using 2,100,302 variants validated for obesity and metabolic traits from imputed single-nucleotide polymorphism (SNP) data. We tested the association of PGS-BMI with SGA-MetS using logistic regression.</p>
RESULTS: GWAS identified suggestive associations (p < 1 × 10-5) on chromosome 15. The variant rs12914956 in CHD2 was associated with increased risk of SGA (odds ratio (OR) = 1.73, 95% confidence interval (CI) = 1.4-2.4, p = 3.6 × 10-7). The gene-based analysis identified significant gene associations with RBFOX1 (p = 4.85 × 10-7), PTPRD (p = 7.6 × 10-7), CSMD1 (p = 2.2 × 10-6), and CHD2 (p = 1.3 × 10-6). The PGS-BMI (β = 0.23, p = 6.8 × 10-5), was associated with increased MetS in a model adjusted for age, sex, physical activity, alcohol consumption, antidepressant medications, schizophrenia diagnosis, and principal components of ancestry.</p>
CONCLUSION: Using a gene-based analysis, we identified significant gene associations with SGA-MetS that have been previously associated with obesity and metabolic traits. The PGS-BMI was associated with MetS, suggesting that a genetic predisposition to a higher BMI may increase the risk of SGA-MetS. Future research should replicate the findings in a larger dataset with more diverse populations.</p>
16 Keywords
- Adult
- Aged
- Antipsychotic Agents
- Biological Specimen Banks
- Body Mass Index
- Cross-Sectional Studies
- Female
- Genome-Wide Association Study
- Humans
- Male
- Metabolic Syndrome
- Middle Aged
- Obesity
- Polymorphism, Single Nucleotide
- UK Biobank
- United Kingdom
12 Authors
- Nihal El Rouby
- Aniwaa Owusu-Obeng
- Michael Preuss
- Simon Lee
- Mingjian Shi
- Michael Lape
- Lisa J. Martin
- Bahram Namjou-Khales
- Leah C. Kottyan
- Sara L. Van Driest
- Jonathan D. Mosley
- Melissa P. DelBello
1 Application
| Application ID | Title |
|---|---|
| 70270 | Investigating genome wide determinants of antipsychotic-induced metabolic syndrome (AP-Mets) using UK Biobank data |
Enabling scientific discoveries that improve human health